Product
COVID-19 Vaccine
16 clinical trials
14 indications
Indication
COVID-19Indication
InfluenzaIndication
LeukemiaIndication
lymphomaIndication
Multiple MyelomaIndication
Inflammatory Bowel DiseaseIndication
COVID-19 vaccineIndication
CancerIndication
Breast CancerIndication
lung cancerIndication
MelanomaIndication
Sickle Cell DiseaseIndication
Liver TransplantClinical trial
A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1083 (SARS-Cov-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of AgeStatus: Active (not recruiting), Estimated PCD: 2024-05-21
Clinical trial
Patient-Reported Outcomes Associated With COVID-19 and Influenza: A Prospective Survey Study on Outpatient Symptomatic Adults With Laboratory-Confirmed Illness in the United StatesStatus: Withdrawn, Estimated PCD: 2024-01-17
Clinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALSStatus: Recruiting, Estimated PCD: 2024-12-05
Clinical trial
A Randomized, Blinded, Two-part, Phase II Trial to Evaluate the Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults 18 Years and OlderStatus: Completed, Estimated PCD: 2022-08-18
Clinical trial
A Phase I/IIa Study to Evaluate Safety and Immunogenicity of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy VolunteersStatus: Completed, Estimated PCD: 2021-09-30
Clinical trial
General Use Results Survey: Spikevax Intramuscular Injection (Previously COVID-19 Vaccine Moderna Intramuscular Injection) During the Early Phase of Treatment With Novel Corona Vaccine, Follow-up of Key Survey ParticipantsStatus: Completed, Estimated PCD: 2023-04-28
Clinical trial
A Phase III, Open Label, Single Arm, Multi-centre, Trial to Assess the Safety and Immunogenicity of a Booster Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Vaccinated Against COVID-19.Status: Completed, Estimated PCD: 2022-03-03
Clinical trial
A Phase 2 Randomized, Multi-center Study of GEO-CMO4S1 (SARS-CoV-2 Vaccine) Versus mRNA SARS-CoV-2 Vaccine in Patients Post Cellular Therapy for Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Randomised, Blinded, Parallel-controlled Phase 1 Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of a COVID-19 mRNA Vaccine in Healthy Adult SubjectsStatus: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of COVID-19 Vaccine(Vero Cell) ,Inactivated in Children and Adolescents Aged 6 Months to 17 YearsStatus: Completed, Estimated PCD: 2023-05-31
Clinical trial
Comparison of the Immune Response to Natural COVID-19 Infection and VaccinationStatus: Recruiting, Estimated PCD: 2024-12-12
Clinical trial
Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel DiseaseStatus: Not yet recruiting, Estimated PCD: 2024-01-01
Clinical trial
Host Immune Response to Novel RNA COVID-19 Vaccination in Patients With Cancer (CTMS# 21-0012)Status: Completed, Estimated PCD: 2022-05-18
Clinical trial
Cancer Therapy and Immunogenicity of COVID Vaccine (CANINE Trial)Status: Active (not recruiting), Estimated PCD: 2024-03-28
Clinical trial
COVID-19 Vaccine Response in People Living With Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Evaluation of the Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver TransplantationStatus: Recruiting, Estimated PCD: 2023-06-30